SCHEMBL24013113

SCHEMBL24013113

Ic1nn(C2CCCCO2)c2ccc(OCc3ccccc3)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.52
CYP4A11 Q02928 3/20 0.52
MAOB P27338 6/20 0.42
MAOA P21397 2/20 0.42
ATR Q13535 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
HTR3A P46098 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.41
GRM5 P41594 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28989533 0.94 MAOB (0.46) CYP4F2CYP4A11MAOBMAOAHTR3A
SCHEMBL27032051 0.89 CYP4F2 (0.42) CYP4F2CYP4A11MAOBMAOAATR
SCHEMBL24013115 0.88 CYP4F2 (0.47) CYP4F2CYP4A11MAOBATRTDP1
SCHEMBL30242615 0.85 CYP4F2 (0.41) CYP4F2CYP4A11MAOBMAOA
SCHEMBL24012964 0.85 CYP4F2 (0.41) CYP4F2CYP4A11MAOBMAOA
SCHEMBL26630588 0.85 L3MBTL1 (0.42) CYP4F2CYP4A11HTR3AALDH1A1SMN1; SMN2
SCHEMBL30242635 0.85 L3MBTL1 (0.42) CYP4F2CYP4A11HTR3AALDH1A1SMN1; SMN2
SCHEMBL28700957 0.83 RXRA (0.41) CYP4F2CYP4A11ATRNPC1RAB9A
SCHEMBL25417349 0.83 CYP4F2 (0.42) CYP4F2CYP4A11MAOBMAOAATR
SCHEMBL31704222 0.83 CYP4F2 (0.42) CYP4F2CYP4A11MAOBMAOAATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors ONCODESIGN PRECISION MEDICINE (FR) 2026-02-10 US disclosed
EP-4146658-B1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PREC MEDICINE OPM (FR) 2025-10-29 EP disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US disclosed
EP-4146658-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2023-03-15 EP disclosed
WO-2021224320-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2021-11-11 WO disclosed
WO-2021224320-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors LRRK2, SNCA, ROS1 CYP4F2 4675/4885CYP4A11 4178/4885MAOB 506/4885
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, RIN1, GRK3 CYP4F2 4470/4885CYP4A11 4478/4885MAOB 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.